-+ 0.00%
-+ 0.00%
-+ 0.00%

*SCYNEXIS Completes Transformative Acquisition Of PXL-770, An Innovative, Highly Selective, Direct AMPK Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) >SCYX

Dow Jones·03/31/2026 10:40:00

Please log in to view news